-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2043 Generation of Functional iPSC-Derived CAR-T Cells for Cancer Immunotherapy Via G9a/GLP Inhibition

Program: Oral and Poster Abstracts
Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster I
Hematology Disease Topics & Pathways:
Research, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Hematopoiesis, Biological therapies, Treatment Considerations, Immunology, Emerging technologies, Biological Processes, Technology and Procedures
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Ran Jing1*, Marcelo Falchetti, Ph.D.2*, Tianxiao Han3*, Mohamad Najia, PhD4*, Luca Hensch5*, Eleanor Meader, PhD2*, Martin Kononov2*, Stephanie Wang2*, Caroline Kubaczka, PhD6*, Edroaldo Lummertz Da Rocha, PhD7*, Robert Grant Rowe, MD, PhD8, Thorsten M. Schlaeger, PhD1*, Marcela Maus, MD9, Trista E. North, PhD10, Leonard I. Zon, MD11,12 and George Q. Daley, MD, PhD1

1Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA
2Stem Cell Program, Boston Children's Hospital and Harvard Medical School, Boston
3Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA
4Harvard Medical School/Boston Children's Hospital, Boston, MA
5Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School; Harvard University, Boston, MA
6Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute; Harvard Medical School; Harvard University, Boston, MA
7Federal University of Santa Catarina, Florianopolis, BRA
8Department of Hematology/Oncology, Harvard Medical School/Boston Children's Hospital, Boston, MA
9Harvard Medical School, Lexington, MA
10Stem Cell Program, Boston Children's Hospital, Harvard Medical School, Boston, MA
11Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital; Howard Hughes Medical Institute; Harvard Medical School; Harvard Stem Cell Institute; Harvard University, Boston, MA
12Howard Hughes Medical Institute, Boston, MA

Cancer immunotherapy using patient-derived T cells modified with chimeric antigen receptors (CAR) has shown exceptional success against lymphoid malignancies. However, these autologous cell therapies involve complex and labor-intensive cell processing. Utilizing human induced Pluripotent Stem Cells (iPSCs) to produce CAR T cells offers significant potential for developing allogeneic, off-the-shelf cancer immunotherapies. The main challenge is generating fully mature T cells from iPSCs, as iPSC-derived T cells often display characteristics of innate-like gamma-delta T cells, lacking the robust functionality of mature alpha-beta T cells derived from peripheral blood. Previously, we developed a stroma-free culture system for differentiating iPSCs into T cells that entailed genetic knockdown of the EZH1 histone methyltransferase, which functions as an epigenetic barrier to hematopoietic maturation (Jing et al, Cell Stem Cell, 2022). To facilitate cell manufacture for clinical translation, we conducted small molecule screens to identify compounds that phenocopy EZH1 deficiency in affecting lymphoid development. We discovered that inhibiting G9a/GLP similarly promotes the generation of mature T cells from iPSC-derived hemogenic endothelial cells (HECs). ATAC-seq and RNA-seq analyses revealed that G9a/GLP inhibition regulates chromatin accessibility and gene expression patterns associated with lymphoid differentiation, and influences the fate choice between myeloid and lymphoid lineages. We also showed that inhibiting G9a/GLP enhances lymphopoiesis in zebrafish, demonstrating the evolutionary conservation of G9a/GLP’s role in T cell development. Most importantly, chemically-induced epigenetic reprogramming via G9a/GLP inhibition enables the generation of highly functional iPSC-derived T cells with a molecular profile similar to that of mature alpha-beta T cells from peripheral blood. Single-cell RNA-seq analysis further revealed that iPSC-derived T cells give rise to both effector and memory-like T cell subpopulations upon activation. When these epigenetically reprogrammed iPSC-derived T cells were engineered to express an anti-CD19 CAR, they showed potent effector responses and antitumor activity in vitro and in a xenograft lymphoma mouse model. We also demonstrated that mice treated with epigenetically modulated iPSC-CAR-T cells were resistant to tumor cell rechallenge, further demonstrating that iPSC-CAR-T cells derived through G9a/GLP inhibition can persist and induce sustained remission. These findings support the efficient production of clinically relevant iPSC-derived T cells for adoptive cell therapies.

Disclosures: Kubaczka: ElevateBio: Research Funding. Zon: CAMP4 Therapeutics: Current holder of stock options in a privately-held company; Fate Therapeutics: Current holder of stock options in a privately-held company; Triveni Bio: Current holder of stock options in a privately-held company; Scholar Rock: Current holder of stock options in a privately-held company.

*signifies non-member of ASH